Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Pegargiminase

Generic Name: Pegargiminase

Drug Type: Small Molecule

CAS Number: 1394129-74-8

Unique Ingredient Identifier: 0B7PYQ9YRT

Overview

Pegargiminase is an anticancer agent.

Background

Pegargiminase is an anticancer agent.

Indication

Investigated for use/treatment in melanoma and hepatocellular carcinoma.

Associated Conditions

No associated conditions information available.

Clinical Trials

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

Phase 2

Completed

Posted: 2018/02/28

Sponsor:Washington Universit...

ID:NCT03449901

Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

Phase 1

Terminated

Posted: 2016/08/23

Sponsor:

Polaris Group

ID:NCT02875093

Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

Phase 1

Completed

Posted: 2014/04/02

Sponsor:

Polaris Group

ID:NCT02101580

Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

Phase 1

Completed

Posted: 2014/04/02

Sponsor:

Polaris Group

ID:NCT02101593

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Phase 1

Terminated

Posted: 2014/01/08

Sponsor:

Polaris Group

ID:NCT02029690

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy